Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Bloomberg reported that Johnson & Johnson (NYSE:JNJ) is exploring a possible ...

While its "AAA" credit rating, robust free cash flow, and low-debt profile offer a defensive haven in a volatile market, the ...

Johnson & Johnson (JNJ) is in focus after releasing long term QUASAR study data showing TREMFYA sustained clinical, ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)’s stock experienced a remarkable ...

Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer’s disease candidate, ...

Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to ...

Bloomberg reports that Johnson & Johnson (NYSE: JNJ) aims to sell its DePuy Synthes Orthopaedics business for more than $20 billion.

Johnson & Johnson (NYSE:JNJ) is frequently grouped with mature healthcare issuers known for repeat distributions over long ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the market is ...